Semler Scientific, Inc. is engaged in developing and marketing technology products and services to healthcare providers to combat chronic diseases. The Company's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The Company delivers QuantaFlo directly to its customers. The Company also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.
企業コードSMLR
会社名Semler Scientific Inc
上場日Feb 27, 2014
最高経営責任者「CEO」Murphy Chutorian (Douglas)
従業員数79
証券種類Ordinary Share
決算期末Feb 27
本社所在地51 E Campbell Ave
都市CAMPBELL
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号95008
電話番号18777744211
ウェブサイトhttps://www.semlerscientific.com/
企業コードSMLR
上場日Feb 27, 2014
最高経営責任者「CEO」Murphy Chutorian (Douglas)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし